Barrett’s Esophagus and Intestinal Metaplasia

Zhang, Lu; Binyu, Sun; Zhou, Xi; Wei, Qiongqiong; Liang, Sisi; Luo, Gang; Li, Tao; Lü, Muhan

doi:10.3389/fonc.2021.630837

Cited by 9 publications

(3 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taking into account the role of acid secretion in esophageal epithelial damage, proton pump inhibitors appear to be actually the only treatment that can interfere with the worsening of histological damage. Indeed, numerous studies have shown that acid-suppressing proton pump inhibitor therapy stabilizes the activity of cellular proliferative cells in the BE and consequently can prevent dysplasia and have a positive impact on reducing the risk of cancer in the esophagus [ 61 , 62 , 63 , 64 , 65 , 66 ] especially if the therapy is continuous and long-term [ 67 ]. The mechanism by which proton pump inhibitors exert a protective effect is nonetheless unclear.…”

Section: Discussionmentioning

confidence: 99%

Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett’s Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens

Crispino

Ciarambino

Giordano

2023

CIMB

View full text Add to dashboard Cite

Barrett’s esophagus (BE) is an acquired pre-malignant condition that results from chronic gastroesophageal reflux. The malignant transformation occurred in 0.5% of patients/year and was independent of medical and endoscopic conservative treatments. Fatty acid synthase (FAS) is a multifunctional enzyme that catalyzes the synthesis of long-chain fatty acids from acetyl-coenzyme A, malonyl-coenzyme A, a reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and adenosine triphosphate. Activation of FAS is closely linked to malignant transformation. The aim of the present study was to evaluate the variation of FAS, p53, and Ki67 expressions in two groups of 21 BE patients each, after one year of continuous (group A) or discontinuous (group B) treatment with esomeprazole 40 mg/day in comparison to the initial expression. In both the two groups of BE patients, biopsies were taken from pathologic sites of the mucosa for histological and immuno-histochemical detection of FAS, Ki67, and p53 at entry and after one year of Esomeprazole 40 mg treatment. FAS expression was positive when a strong granular cytoplasmic staining was observed in esophageal cells. Ki67 and p53 were defined as positive when nuclear staining was clearly detected at ×10 magnification. FAS expression was reduced in 43% of patients treated with Esomeprazole continuously in comparison to the 10% of patients treated with Esomeprazole on demand (p = 0.002). Ki67 expression was reduced in 28% of continuously treated patients in comparison to 5% of patients treated on demand (p = 0.001). The p53 expression decreased in 19% of continuously treated patients in comparison to an increase in 2 patients (9%) treated on demand (p = 0.05). Continuously Esomeprazole treatment could help in the diminution of metabolic and proliferative activities in the esophageal columnar epithelium and in part it can help prevent the oxidative damage against cellular DNA, resulting in a diminution in p53 expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett’s Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens

Crispino

Ciarambino

Giordano

2023

CIMB

View full text Add to dashboard Cite

show abstract

“…Metaplasia describes transformation of a fully differentiated cell type into other cell types as tissues change into entirely different tissue types. The concept gained popularity in the 1800s, was based on histological and anatomical observations, and is often discussed in terms of pathological changes in tissue in response to environmental insult such as with Barrett’s esophagus (Zhang et al 2021) or in the context of cancer as reviewed (Giroux and Rustgi 2017). However, recent evidence suggests that metaplasia and cellular plasticity contribute to development and regeneration within the musculoskeletal system and beyond (Kaji et al 2020; Brown et al 2022; Goldenring and Mills 2022).…”

Section: Paligenosis: a Process Of Metaplasia In Multicellular Organismsmentioning

confidence: 99%

A Shifting Paradigm: Transformation of Cartilage to Bone during Bone Repair

2022

View full text Add to dashboard Cite

While formation and regeneration of the skeleton have been studied for a long period of time, significant scientific advances in this field continue to emerge based on an unmet clinical need to improve options to promote bone repair. In this review, we discuss the relationship between mechanisms of bone formation and bone regeneration. Data clearly show that regeneration is not simply a reinduction of the molecular and cellular programs that were used for development. Instead, the mechanical environment exerts a strong influence on the mode of repair, while during development, cell-intrinsic processes drive the mode of skeletal formation. A major advance in the field has shown that cell fate is flexible, rather than terminal, and that chondrocytes are able to differentiate into osteoblasts and other cell types during development and regeneration. This is discussed in a larger context of regeneration in vertebrates as well as the clinical implication that this shift in understanding presents.

show abstract

“…Gastric mucosal IM is a pathological process in which intestinal epithelial cells replace gastric mucosal epithelial cells, that is, there are epithelial cells similar to the intestinal mucosa in the gastric mucosa (Abdelfattah et al, 2021 ; Jonaitis et al, 2021 ; Zhang et al, 2021 ; He et al, 2022 ). IM is common in the stomach and esophagus, but can also be seen in the gallbladder, bile duct, uterus, bladder, pelvis, ureter, and urethra (Deniz et al, 2010 ; Rubio et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Differences in gastric microbiota and mucosal function between patients with chronic superficial gastritis and intestinal metaplasia

Jiang

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Chronic superficial gastritis (CSG) and intestinal metaplasia (IM) can further develop into gastric cancer, which seriously endangers the health of people all over the world. In this study, the differences in gastric microbiota between CSG patients and IM patients were detected by 16S rRNA gene sequencing. As the expression levels of mucin and CDX2 are closely related to IM, the expression differences of mucin (MUC2 and MUC5AC) and CDX2 in the gastric mucosa of CSG patients and IM patients were detected by Western blot and qRT-PCR. The results showed that both Faith_pd and Observed_species indexes of microbiota in the gastric juice of CSG patients were significantly higher than those of IM patients. At the genus level, Thermus and Anoxybacillus were dominant in the gastric juice of IM patients, and Helicobacter was dominant in the gastric juice of CSG patients. Non-metric multidimensional scaling (NMDS) demonstrated that the dispersion of samples in the CSG group is greater than that in the IM group, and some samples in the CSG group are clustered with samples in the IM group. The KEGG metabolic pathway difference analysis of gastric juice microbiota in CSG and IM patients revealed that the gastric juice microbiota in the CSG and IM patients were significantly enriched in the amino acid metabolism, carbohydrate metabolism, and metabolism of cofactors and vitamins, and the functional differences between the two groups were mainly concentrated in the bacterial secretion system (VirB1, VirB2, VirB3, VirD2, and VirD4). In conclusion, there are significant differences in gastric microbiota and mucosal function between the CSG and IM patients. Moreover, the results of this study may provide a new means for the detection of CSG and IM and a new direction for the prevention and treatment of CSG and IM.

show abstract

Barrett’s Esophagus and Intestinal Metaplasia

Cited by 9 publications

References 118 publications

Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett’s Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens

Variation in Fatty Acid Synthase, Ki67 and p53 Esophageal Mucosa Expressions in Barrett’s Esophagus Patients Treated for One Year with Two Esomeprazole Different Regimens

A Shifting Paradigm: Transformation of Cartilage to Bone during Bone Repair

Differences in gastric microbiota and mucosal function between patients with chronic superficial gastritis and intestinal metaplasia

Contact Info

Product

Resources

About